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Abstract:
Aim: The main aim of our study was to improve solubility of Clopidogrel bisulphate by preparing 
nanosuspensions using solvent-antisolvent (bottom up) technology.
Methods: Clopidogrel nanosuspensions were formed by solvent antisolvent method. 15 formulations were 
prepared with different concentrations at different ratios. These formulations were evaluated for mean particle 
size, solubility, drug content and maximum yield. The selected formulation was then compared with pure drug 
for various parameters such as X-ray diffraction, Scanning Electron Microscopy, in-vitro Dissolution studies, 
Fourier Transform – Infrared Radiation (FT-IR) etc. Release kinetics and stability studies were performed for 
the optimized formulation.
Results: Out of 15 formulations, F15 comply well with all the parameters. On comparison with pure drug, F15 
showed better characteristics such as Fourier Transform- Infrared Radiation (FT-IR), Solubility, particle size, 
Scanning electron microscopy, in-vitro dissolution, X-ray diffraction etc. Optimized formulation showed first 
order kinetics and stability was shown for over 3 months.
Conclusion: Clopidogrel (anti-platelet) in nanosuspension formulation can overcome the limitation of low 
solubility, dissolution, bioavailability and explore further.
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INTRODUCTION:
Heart attack (myocardial infarction) is found to be 
the most common cause of death in the developed 
countries. Formation of a blood clot within the 
heart artery forms the etiology of MI. Today, arrays 
of antiplatelet drugs are available that can be used 
to prevent heart attack by preventing clump and 
clot formation. However, the poor solubility of 
these drugs remains one of the major challenges 
addressed by pharmaceutical scientists [1]. At 
present, about 10% of the drugs in clinical use have 
bioavailability problems due to poor solubility. The 
poor solubility of drug causes hinderances in 
pharmacological screening of compounds for 
potential drug effects. Hence, improving the 
saturation solubility and dissolution rate of poorly 
water-soluble drugs is very important and 
significantly challenging to pharmaceutical 
researchers [2].
Clopidogrel, a potent anti-platelet drug, selectively 
inhibits the binding of adenosinediphosphate 
(ADP) to its platelet receptor [3]. It is indicated for 
the prevention of vascular thrombotic events in 
patients at risk [4]. According to the 
biopharmaceutics classification system (BCS), 
Clopidogrel is categorized as a class II agent 
(poorly water soluble and highly permeable) [5]. 
Oral bioavailability of Clopidogrel is very low (less 
than 50%), due to this poor water solubility. It is 
practically insoluble in water at neutral pH [6]. 
To overcome this problem, one possible way could 
be the formulation of this drug using 
nanotechnology. Nanosuspension consists of the 
poorly water soluble drug without any matrix 
material suspended in dispersion [7]. These can be 
used to enhance the solubility of drugs that are 
poorly soluble in water as well as lipid media. This 
approach can be useful for Clopidogrel like drugs 
to improve their antithrombotic activity which 
possess a significant challenge for the formulators. 
The most important feature of nanosuspension is 
the increase in saturation solubility as well as 
dissolution velocity of the compound. The aim of 
this work is to formulate the Clopidogrel 
nanosuspension by antisolvent precipitation method 
and find out the effect of stabilizer (alone and in 
combination) on the formulation, when all 
parameters of operation are kept constant. To 
overcome the particles growth, lyophilization was 
carried out in order to assess the feasibility of 
transferring nanosuspensions to a dry powder 
[8][9]. 
The main aim of our study is to improve solubility 
of potent BCS Class-II drug (Clopidogrel) by 
preparing nanosuspensions using solvent-
antisolvent (bottom up) technology. The above 
objectives were framed to enhance drug release in 
shorter duration of action as well as improve 
solubility and oral bioavailability. 
MATERIALS AND METHODS:
Clopidogrel was obtained as a gift sample from 
Tirupati Medicare, Baddi (Himachal Pradesh). All 
the other raw materials were of analytical grade and 
of high purity, purchased from local source. 
Instruments were validated and laboratory 
conditions were well maintained throughout the 
entire procedure. 
Before starting with the formulation development, 
the pre-formulation studies were conducted to 
characterize the drug and to select the excipients 
based on the pre-formulation studies. 
Preformulation studies involves hygroscopicity, 
solubility, partition coefficient as well as 
compatibility studies [10][11]. 
The hygroscopicity of Clopidogrel was determined 
as per “European Pharmacopoeia” and slight 
modification of Callan procedure. Solubility studies 
utilise shake flask method to determine solubility 
of the drug. To determine the partition coefficient 
of the API the shake flask method was used; it is 
the classical and the most useful method of 
determination of partition coefficient. The partition 
coefficient of Clopidogrel between n-octanol & 
water was determined by slight modification of 
“Shake Flask Method”, at room temperature The 
samples prepared for physical compatibility study 
were also evaluated for chemical incompatibility 
after 28 days of physical evaluation using FT-IR 
analysis.  
Formulation development of nanosuspension was 
started with the selection of main ingredients 
(excipients) involved in its preparation. The main 
excipients of nanosupesion include stabilizers, 
solvents and antisolvents. Ethanol, acetone and 
methanol were selected on the basis of solubility of 
drug and rapid miscibility with solvent-miscible 
antisolvent. For the effective size reduction of the 
drug particles, water soluble polymers and 
stabiizers have been used to inhibit the particles 
agglomeration and improve the physicochemical 
properties of the drug. Common pharmaceutical 
excipients that are suitable for use as polymeric 
stabilizers include the cellulosics, such as 
Hydroxypropyl methyl cellulose (HPMC), and 
pluronics (F68 and F127) and surfactant like tween 
80.The Stabilizers were added in ratio of 0.1 % 
(w/v) in the antisolvent (water in most of the 
cases). 
Clopidogrel nanosuspensions were prepared in 
accordance with the liquid antisolvent precipitation 
technique. Clopidogrel and surfactants were 
dissolved in organic solvents such as methanol, 
ethanol or acetone at different concentrations to 
form the organic phase. The antisolvent phase was 
prepared by dispersing the stabilizers in water. The 
organic solution was rapidly introduced into 
antisolvent solution under vigorous agitation. The 
vigorous agitation results in the formation of 
clopidogrel nanosuspensions [12].
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Formulations design for Nanosuspension 
In this section, eight formulations were taken in 
which different solvents and antisolvents with 
different concentrations were added. The drug 
concentrations in these formulations (F1 to F8) 
were added in an unchanged amount i.e 20 mg as 
shown in Table 1. In the formulations F1 to F4, 
acetone is added as a solvent and water is added as 
an antisolvent in different concentrations. In the 
formulations F5 to F8, ethanol is added as a solvent 
and water as an antisolvent in different 
concentrations. The ratio of antisovent to solvent 
taken is 1:10, 1:20, 1:50 and 1:100. 
In this section, the ratio of antisolvent to solvent 
was kept constant i.e 1:20 and ethanol (as solvent) 
and water (as antisolvent) were added to 
formulations F9 to F12. In this parameter, different 
concentrations (10 mg, 20 mg, 50 mg and 100 mg) 
of drug Clopidogrel were added in the formulations 
F9 to F12 as shown in Table 1. After this, the best 
drug concentration was selected for further 
parameters. In this section, different stabilizing 
agents were added in the premeasured quantity. In 
formulation F13, HPMC E5 is added in 0.1% 
(w/v), Tween 80 and Poloxomer were added to the 
formulations F14 and F15 in the same quantity. 
The ratio of antisolvent to solvent is kept constant 
i.e 1:20 for all three formulations. Ethanol and 
Water were added as solvent and antisolvent(F13 to 
F15) as shown in Table 1. 
Table 1: Formulation of clopidogrel nanosuspension using different stabilizer at different ratios.
Formulation 
code
Solvent
Anti-
solvent
Clopidogrel 
( mg)
Solvent-
antisolvent 
ratio
Stabilising
agent % 
w/v
Stabilising
agent % 
w/v
Stabilising
agent % 
w/v
HPMC E5 Tween-80
Poloxamer 
F-68
F1 Acetone Water 20 01:10 - - -
F2 Acetone Water 20 01:20 - - -
F3 Acetone Water 20 01:50 - - -
F4 Acetone Water 20 1:100 - - -
F5 Ethanol Water 20 01:10 - - -
F6 Ethanol Water 20 01:20 - - -
F7 Ethanol Water 20 01:50 - - -
F8 Ethanol Water 20 1:100 - - -
F9 Ethanol Water 10 01:20 - - -
F10 Ethanol Water 20 01:20 - - -
F11 Ethanol Water 30 01:20 - - -
F12 Ethanol Water 50 01:20 - - -
F13 Ethanol Water 20 01:20 0.1 - -
F14 Ethanol Water 20 01:20 - 0.1 -
F15 Ethanol Water 20 01:20 - - 0.1
F: Formulations; HPMC: Hydroxypropylmethyl cellulose; Clopidogrel drug was used in milligrams
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Characterization 
Percentage Drug Content: To determine the 
encapsulation efficiency dissolved 10 mg of 
nanosuspension in 30 ml methanol and then 
sonicate under vigorous shaking for 1 hour. The 
resultant solution was centrifuged. The drug 
content in supernatant solution was analyzed 
spectrophotometically by using ultraviolet-visible 
(UV-VIS) spectrophotometer at 271 nm with 
further dilutions against appropriate blank. 
Percentage Solubility: The percentage solubility 
of clopidogrel bisulphate was determined by 
mixing 10mg of the nanosuspension formulation 
with approximately 2 ml of the distilled water taken 
in a glass vials with rubber stopper. Then the vials 
were kept on shaking on a water bath shaker for 24 
hrs at room temperature. After 24 hrs the vials were 
centrifuge with centrifugal machine at rpm 1500-
3000 for 10 mins. Then the supernatant liquid was 
pipette out from each vials and the solubility was 
determine in UV-Visible spectrophotometer 
(Shimadzu 1800, Japan) at 200-800 nm 
respectively.  For each formulation the experiment 
was repeated in triplicate.
Particle Size: The mean particle size was 
determined using optical microscope. In this 
method, the size of 250 particles was determined 
and the average particle size was calculated. Thus, 
a particle size analyser is being further used for the 
accurate size determination [13]. 
Percentage Yield: To determine the yield, the 
weight of nanosuspension obtained at the end of 
preparation was determined. The total weight of 
raw materials used to obtain this nanosuspension 
was determined to obtain the theoretical yield. 
On the basis of above parameters, an optimum 
formulation was selected which complies with in 
all the parameters and will be evaluated against 
marketed formulataion.
Evaluation of optimised formulation
Based on the parameters discussed above, an 
optimised formulation was selected and evaluated 
with pure drug. The evaluation was done using 
various parameters such as X-ray diffraction 
studies, Differential Scanning colorimeter, 
Scanning electron microscopy, in-vitro Dissolution 
studies etc.
Particle Size
The mean particle size was determined using 
optical microscope. In this method, the size of 250 
particles was determined and the average particle 
size was calculated. Thus, a particle size analyser is 
being further used for the accurate size 
determination [13]. 
Zeta Potential 
In this study, the zeta potential was assessed by 
determining the electrophoretic mobility of the 
particles. The zeta potential was measured using a 
Zetasizer Nano 1000 HS (Malvern Instruments, 
Malvern, UK). Samples were diluted with the 
respective original dispersion medium, which 
provides information regarding the thickness of the 
diffuse layer. Diluted nanosuspension was added to 
the sample cell (quartz cuvette) and was put into 
the sample holder unit and zeta potential was 
measured. The Zetasizer range provides 
exceptionally high performance that can measure a 
particle size from less than a nanometer in size to 
several microns. This system measures particle size 
using dynamic light scattering [14].
FT-IR Studies
An FTIR spectrometer simultaneously collects high 
spectral resolution data over a wide spectral range. 
This confers a significant advantage over a 
dispersive spectrometer which measures intensity 
over a narrow range of wavelengths at a time. The 
term Fourier transform infrared spectroscopy 
originates from the fact that a Fourier transform (a 
mathematical process) is required to convert the 
raw data into the actual spectrum. The prepared 
samples were scanned in the range from 650 cm-1-
4000 cm-1 [15][16]. 
X-ray Diffraction Analysis
X-ray diffraction (XRD) is the basic 
characterization technique for structural and phase 
analysis. Crystal nature of a sample is determined 
by X-ray diffraction analysis. This diffractometer 
uses copper-potassium radiation having a 
wavelength of 1.5418 Å.  The sample is kept 
horizontally and can be rotated using a spinner 
sample stage.  The X-ray tube was operated at 45 
kV and 40 mA current [17]. 
SEM (Scanning electron microscopy)
In order to examine the particle surface 
morphology and shape, scanning electron 
microscopy (SEM) was used. A concentrated 
aqueous suspension was spread over a slab and 
dried under vacuum. It gives information about the 
particle size distributed in the nanosuspension. 
Schematic diagram of SEM is shown in Fig.5.7 
(left). SEM micrographs of the samples were 
obtained using ZEISS EVO-50 scanning electron 
microscopes presented in Fig.5.8 (right). SEM 
measurements are based on the principle of 
irradiating the specimen with a fine focused 
electron beam. The secondary electrons, 
backscattered electrons, auger electrons, 
characteristic X-rays and several other radiations 
are released from the specimen. Generally, the 
secondary electrons are collected to form the image 
in the SEM mode [18]. 
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Differential Scanning Calorimetry (DSC)
DSC can be used to determine the compatibility 
between the drug and excipients and also used to 
evaluate the crystalline state of drug especially 
when converted to nanoparticles. Thermal 
characteristics of the same materials that examined 
in FTIR study were determined by DSC 4000 from 
Perkin Elmer, USA. Accurately weighed samples 
(5mg) were placed in nonhermetically aluminium 
pans and heated at the rate of 10 ºC/minute against 
an empty aluminium pan as a reference covering a 
temperature range of 25 ºC to 300 ºC [19]. 
In-vitro Dissolution Studies
The dissolution studies of powder nanosuspension 
were carried out in dissolution apparatus (USP 
apparatus II) in 100 ml of phosphate buffer pH 6.8 
as a dissolution medium, maintained at 37 ± 0.5°C. 
The medium stirred at 100 rpm. Aliquots 1 ml of 
the dissolution medium was withdrawn at 15, 30, 
45, 60, 90, 120 and 180 mins time interval and the 
same amount was added with the fresh medium in 
order to maintain the sink conditions. Samples were 
assayed spectrophotometerically on UV-Visible 
spectrophotometer [13][20]. 
Release kinetic model 
The in vitro release data obtained were fitted in to 
various kinetic equations. The value of R2 was 
more in first order drug release. The value on n is 
0.45<n<0.89 that is non ficckian diffusion [21]. 
Stability Studies of Optimized Formulation as 
per ICH guidelines
The stability studies were carried out as per ICH 
Q1A/(R2) guidelines for the optimized formulation. 
The formulation was stored at 40° ± 2°C/75% ± 5% 
RH for the duration of 3 months. The samples was 
analysed for physical changes and drug content 
after interval of 0, 30, 60, and 90 days. Physical 
stability was analysed by appearance, colour and 
the chemical stability was analysed by percent drug 
entrapment [13].
RESULTS:
Preformulation study of drug is an important step 
for formulation development. The preformulation 
studies of Clopidogrel include determination of 
hygroscopicity, solubility profile, partitioning etc.  
Hygroscopicity of Clopidogrel to moisture was 
determined according to European Pharmacopeia 
and procedure defined by Callan et al. The total 
moisture absorbed was assessed in terms of total 
weight gain by Clopidogrel when exposed to 
25°C/80±2% RH for 24 hrs & 25±1°C/90±2% RH 
for 7 days in humidity chamber as shown in Table 
2. The total weight gain after 7 days was only 
0.067±0.012 % at 25±1°C/90±2% RH whereas 
negligible weight gain was observed at 
25±1°C/80±2% RH in 24 hrs. Therefore, it could 
be concluded that the procured Clopidogrel sample 
is non hygroscopic in nature as per specifications of 
European Pharmacopoeia and Callan classification.
Table 2: Hygroscopicity of Clopidogrel
Original 
Weight 
Taken (mg)
Weight (in mg) ± S.D. after exposure 
at
Total weight gain 
(in mg) ± S.D after
% weight gain (in mg) ± 
S.D after
Inference
25±1°C/80±2 
%RH for 24 
hrs
25±1°C/90°C 
±2%RH for 7 days
24 hrs 7 days 24 hr 7 days
300 300.01 ± 0.028 300.02 ± 0.039
0.01 ± 
0.028
0.02 ± 
0.039
0.003 ± 
0.007
0.0067 ± 
0.012
Non-
hygroscopic
S.D: Standard Deviation
The solubility studies of drug were conducted in different solvents and the results of which are listed below in 
Table 3. It was observed that the drug Clopidogrel has higher solubility in ethanol as compare to other solvents.
Table 3: Solubility of drug in various solvents
S.No. Name of solvent Solubility (mg/ml)
1 Water 0.04±0.0023
2 Ethanol 1.50±0.0078
3 Acetone 0.81±0.012
4 Methanol 0.84±0.0023
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The Partition coefficient of Clopidogrel was 
determined between n-Octanol and water using 
‘shake flash method’. Thus experimentally 
observed value and theoretical value of partition 
coefficient is tabulated in Table 4.
Table 4: Partition coefficient of drug
Organic 
Phase
Aqueous 
Phase
Theoretical 
value
Practical 
value
n-
Octanol Water 3.89 4.15±0.72
The drug-excipients sample was taken in 1:1 ratio 
and tested for its physical characterization at three 
different temperatures and humidity levels such as 
25 °C /60%RH, 30°C /65%RH, 40°C /75%RH for  
4 weeks. After completion of physical 
compatibility, the samples were analyzed for 
physicochemical interaction between drug and 
polymer by FT-IR analysis. 
The FT-IR spectra obtained for pure drug, 
excipients and the physical mixture of drug and 
excipients is given in the Figure 1. Excipients, e.g. 
Poloxomer shown in Figure 1(b) have shown 
characteristic peaks at 1100 cm-1 corresponding to 
its functional group -C-O, indicating its purity and 
authenticity. Similarly, Tween 80 and HPMC also 
show their respective characteristic peaks well 
matched with literature, shown in Figure 1(c)-(d).  
No appreciable change was observed in absorption 
peaks of drug when loaded with the physical 
mixture of excipients (Figure 1(e)-(g). Therefore, it 
can be concluded that there was no chemical 
interaction existing between drug and excipients.
Fig 1: FT-IR spectrum of (a) pure Clopidogrel drug (b) Poloxomer (c) Tween 80, (d) HPMC; physical 
mixture of (e) Clopidogrel drug and Poloxomer (f) Clopidogrel drug and Tween 80 (g) Clopidogrel drug 
and HPMC
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Formulation Development of Nanosuspension 
In order to develop Nanosuspenion of Clopidogrel, 
various excipients were selected based on 
preformulation studies. The main excipients 
(ingredients other than API) of nanosupension 
include stabilizer, solvent and antisolvent. Effect of 
anti-solvent to solvent ratio on particle and 
percentage solubility is given in a Table 5. In this 
section, eight formulations were taken in which 
different solvents and antisolvents with different 
concentrations were added. The drug concentration 
added in these formulations (F1 to F8) was added 
in an unchanged amount i.e 20 mg. In the 
formulations F1 to F4, acetone is added as a solvent 
and water is added as an antisolvent in different 
concentrations. In the formulations F5 to F8, 
ethanol is added as a solvent and water as an 
antisolvent in different concentrations. It was also 
found that Formulation code i.e. F1 to F8 has 
percentage drug content 67.45±3.89 to 88.23±3.02, 
percentage solubility 60.87±3.65 to 82.89±2.54, 
percentage yield 70.25±0.075 to 82.74±0.016 and 
particle size 0.98±0.21to 1.39±0.25µm. It was 
found that formulation F6 has highest percentage 
solubility, highest percentage yield and smaller 
particle size. Now it shows that anti +solvent to 
solvent ratio in ethanol is showing better results i.e. 
1:20 as comparison to anti solvent to solvent ratio 
in acetone on increasing anti-solvent to solvent 
ratio particle size was reduced. If the ratio of 
antisolvent to solvent is increased, the degree of 
supersaturation ratio is increased. This increases 
the nucleation rate and increase the particle size; 
possibly due to equilibration of nucleation and 
growth kinetics.   
Effect of drug concentration on particle size, 
percentage % Drug content, and percentage yield 
and percentage solubility is given in Table 5. For 
this purpose, ethanol (as solvent) and water (as 
antisolvent) were added (chosen from results of the 
Table 3) in the constant ratio of (solvent to 
antisolvent) 1:20 in formulations F9 to F12. Then, 
different concentrations (10 mg, 20 mg, 50mg and 
100mg) of drug Clopidogrel were added in these 
formulations F9 to F12. From the table it was found 
that Formulation code i.e. F9 to F12 has percentage 
drug content 83.65±4.32 to 88.23±3.02, percentage 
solubility 81.48±4.25 to 87.98±2.01, percentage 
yield 74.28±1.56 to 82.74±2.01 and particle size 
0.98±0.21 to 1.54±0.21µm. It was found that 
formulation F10 has highest percentage solubility, 
highest percentage yield and smaller particle size. 
Hence the formulation F10 contains the best drug 
concentration for Clopidogrel nanosuspension and 
it was selected for further optimization.
Effect of different stabilizer on particle size, 
percentage % Drug content, percentage yield and 
percentage solubility was given in a Table 5. For 
this, different stabilizing agents were added in the 
premeasured quantity.In formulation F13, HPMC 
E5 is added in 0.1% (w/v), Tween 80 and 
Poloxamer were added to the formulations F14 and 
F15 in the same quantity. The ratio of antisolvent to 
solvent is kept constant i.e 1:20 for all three 
formulations. Ethanol and Water were added as 
solvent and antisolvent (F13 to F15).Three 
stabilizers Poloxamer, Tween80 and HPMC E5 
were added in a premeasured quantity of the drug. 
As it is clear from the table that  among these three 
formulations, F15 formulation (that contain 
poloxamer as a stabilizer) was found to exhibit 
smallest particle size, highest drug content, 
maximum percentage yield and greatest solubility. 
Therefore, F15 formulation is considered as the 
best formulation among all formulations used to 
formulate Clopidogrel nanosuspension and will 
undergo for the evaluation study
Table 5: Particle size, Entrapment Efficiency, Yield and solubility of different nanosuspension 
formulation
S.No. Formulation code % Drug content Solubility (in % age) Yield (in % age) Particle size (µm)
1 F1 78.34±3.32 64.32±3.74 72.35±3.17 1.11±0.25
2 F2 75.23±2.96 63.78±3.12 76.85±3.45 1.15±0.12
3 F3 68.23±3.25 65.23±3.78 74.85±4.25 1.56±0.18
4 F4 67.45±3.89 60.87±3.65 70.25±3.75 1.01±0.21
5 F5 79.68±4.01 76.98±3.89 71.58±3.14 1.06±0.41
6 F6 88.23±3.02 87.98±2.01 82.74±2.16 0.98±0.21
7 F7 81.45±3.58 82.89±2.54 79.65±3.78 1.32±0.38
8 F8 80.78±4.11 79.68±3.85 74.89±3.21 1.39±0.25
9 F9 83.65±4.32 84.21±2.65 74.28±1.56 1.58±0.25
10 F10 88.23±3.02 87.98±2.01 82.74±2.01 0.98±0.21
11 F11 87.55±2.58 82.46±3.25 80.36±2.65 1.33±0.18
12 F12 84.52±4.25 81.48±4.25 79.89±2.87 1.54±0.21
13 F13 84.15±4.32 86.24±2.89 83.38±2.58 1.25±0.35
14 F14 86.56±3.02 89.98±1.98 86.74±3.33 1.052±0.19
15 F15 91.84±3.54 92.58±3.12 90.36±1.98 1.04±0.16
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Evaluation of Nanosuspension 
Particle Size Analysis
Formulation code F15 was selected for size 
determination using particle size analyzer. On 
evaluation particle size formulation was found to 
be around 358 nm and Polydispersity Index (PDI) 
of the formulation was 0.200 as shown in Figure 2. 
Zeta potential
In general, zeta potential of particles should be at 
least ±30 mV for electrostatically stabilized 
systems or ±20 mV for sterically stabilized systems 
to obtain a physically stable nanosuspension. The 
zeta potential of optimized nanosuspension was 
found to be -13.5 mV as shown in Figure 3, 
indicating that the prepared nanosuspension do not 
suffer from instability problems. Zeta potential of
nanosuspension exhibited no essential changes 
before and after the storage and stability studies. 
Fig 2: Particle size distribution of formulation F15
Fig 3: Zeta Potential of formulation F15.
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FT-IR Studies
There was no incompatibility between drug and 
other solvents and ingredients as shown in Figure 
4(A) and 4 (B). The results showed that the 
characteristic peak of Clopidogrel was 1747 cm-1 
which is due to C=O stretching of the ester as a 
functional group present in all the spectrum 
indicating that there is no chemical interaction 
between the Clopidogrel (pure and lyophilized 
powder) and the other excipients. IR spectrum of 
Clopidogrel is characterized by principal 
absorption peaks at 3113.16cm-1 (C-H aromatic), 
1748.41.36cm-1 (C=O stretching), 1176.36cm-1 
(C-O stretching) as shown in Table 6.
A
B
Fig 4: A) FTIR of Drug Clopidogrel and B) Formulation (F15)
Table 6: FT-IR spectral peaks or pure drug and formulation (f15)
S.No. Observed  peak  in Observed  peak  in Inferences
pure drug (cm-1) Formulation (F15) (cm-1)
1 1176.36 1165.97 C-O stretching
2 1747 1751.11 C=O  stretching  of the ester
3 1748.41 1752 C=O stretching
4 3113.16 3161 C-H aromatic
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X-ray Diffraction (XRD) 
XRD pattern (in 2θ range 10° ≤ 2θ ≤ 70°) of pure 
drug and and the nanosuspension F15 was shown in 
Figure 5. These patterns were taken at very slow 
scan rate (step size 0.01°, scan time per step 50 s). 
The X-ray patterns of the Clopidogrel powder 
displayed the presence of numerous narrow and 
symmetrical diffraction peaks, indicated the 
crystalline structure of the drug, while XRD for 
nanosuspension powder F15, as expected, no sharp 
peak drug was observed. This indicates that the 
crystalline structure of Clopidogrel was lost 
because of the precipitation and lyophilization of 
the drug.
Scanning electron microscopy
Well defined grains represent polycrystalline nature 
of the pure drug sample as shown in Figure 6(A). 
However, the SEM of formulation F15 as shown in 
Figure 6(B) did not show any particular granular 
structure, thus represents amorphous nature of 
formulation.   
Figure 5: X-Ray  diffraction  patterns  of  pure  drug  and  nanosuspension  F15 formulation
A                                                                                                                    B
Figure 6: A) SEM of drug and (B) F15 formulation
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Differential Scanning Calorimetry (DSC)
The solvent -antisolvent process of nanosuspension 
formation may change the physical state of 
Clopidogrel drug. Figure 7(A) shows the DSC 
curves of raw clopidogrel showed a single sharp 
endothermic peak at 179 °C which corresponded to 
its melting point. This result is also supported by 
our melting point measurement discussed earlier. 
Figure 7(B) represent the DSC curve for 
nanosuspension formulation F15. In this 
lyophilized powder, the melting point peak of 
Clopidogrel disappeared which reveals that the 
drug lose the crystalline state and converted to an 
amorphous form, as also indicated in the XRD data. 
In-vitro drug release study
Percentage Drug release of F15 formulation and 
pure drug was given in below Table 7. Form the 
Figure 8, it was found that in vitro drug release 
nanosuspension was higher and faster as compare 
to pure drug. 
A                                                                    B
Figure 7: (A) DSC of clopidogrel drug (B)DSC of Clopidogrel Nanosuspension formulation F15.
Table 7: Percentage Drug release of F15 formulation
S. No. Time (Min.)
% Drug release (Pure 
Drug)
% Drug release (F15 
formulation)
1 15 0±0 25.36±1.26
2 30 3.64±0.22 38.74±2.14
3 45 7.2±0.81 52.65±3.12
4 60 14.79±0.62 66.74±3.41
5 90 18.2±1.48 72.36±3.11
6 120 23.62±1.02 74.85±2.96
7 180 29.04±1.32 76.52±2.85
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Figure 8: In-vitro drug release of F15 formulation and pure drug
Drug release and kinetics  
Model dependent methods are based on different 
mathematical functions, which describe the release 
profile. Once a suitable function has been selected, 
the release profiles are evaluated depending on the 
derived model parameters. In vitro kinetic analysis 
showed that drug release was best explained by 
First order kinetics equation, with highest value of 
linearity (R2 > 0.9) for F15 formulation.   
Stability Studies 
The stability studies were carried out as per ICH 
guidelines for the optimized formulations. The 
nanosuspension (F 15) was stored at 40°C ± 
2°C/75%± 5%RH for the duration of  3 months.The 
stability studies showed that there was no change in 
the appearance and colour of nanosuspension 
indicating that the optimized formulation F15 was 
physically stable at the conditions to which they 
were exposed as shown in Table 8. It was observed 
that there was very slight reduction in the drug 
content of the nanosuspension which were stored at 
40°C ± 2°C/75%± 5%RH after storage for 90 days 
and the optimized formulation F15 did not show 
any significant change in drug content during 
stability study and is found to be stable.
Table 8: Evaluation of physical stability and chemical stability (% drug content) of optimized formulation
Time (days) Physical change Chemical Change
Appearance Colour % drug Absorption
entrapment maxima (nm)
0 NC White 91.84 ± 3.54 271
30 NC White 91.33 ± 3.40 271
60 NC White 90.89 ± 1.98 271
90 NC White 90.37 ± 2.65 271
NC: No Change
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DISCUSSION:
Poor solubility of drug is one of the major 
problems currently being addressed by 
pharmaceutical scientists at industry and academia. 
At present, about 10% of the drugs in clinical use 
have bioavailability problems due to poor 
solubility. The decreased solubility of drugs makes 
it very difficult to perform the pharmacological 
screening of compounds for potential drug effects. 
Hence, improving the saturation solubility and 
dissolution rate of poorly water-soluble drugs is 
very important and significantly challenging to 
pharmaceutical researchers seeking to achieve 
optimum absorption of new drug candidates. 
The purpose of this work was to enhance solubility 
of Clopidogrel drug and provide rapid onset of 
action. The effort has been made to find out the 
best formulation for Clopidogrel nanosuspension. 
Clopidogrel is a BCS class-II drug having low 
solubility and high permeability. Thus, it was
challenging to enhance the solubility of 
Clopidogrel in an aqueous solution. Precipitation 
antisolvent method has been employed to produce 
nanosuspension of Clopidogrel. The different 
formulate variables such as sovent, antisolvent and 
Surfactant ratios were contributing much towards 
the change in particle size and solubility in 
nanosuspension preparation. 
Initially solubility study was carried out by taking 
drug in different solvents and drug-excipient 
compatibility study was determined by FTIR 
method. The physical state of pure drug was 
examined by DSC technique and the prepared 
nanosuspension was evaluated for particle size, 
Polydispersity index (PDI), Zeta potential, 
percentage yield , percentage drug content, In-vitro 
dissolution study and short term stability study. The 
solubility rate of Clopidogrel in different solvent is 
shown in Figure 1. FTIR spectra of pure drug 
Clopidogrel and physical mixture of drug with 
excipients like poloxomer, Tween 80, HPMC E5 
shows no chemical interaction between drug and 
excipients. On preformulation evaluation melting 
point and partition coefficient was found to be 176-
180°C±0.95oC and 4.15±0.72, represent lipophilic 
nature of drug. Ethanol has higher drug solubility 
as compare to other solvents. Standard calibration 
curve was prepared in methanol using 
concentration range 1μ/ml-10μg/ml. R2 value was 
found to be 0.998. 
Fifteen different batches (F1 –F15) with different 
solvent antisolvent ratio, different drug 
concentration and different type of stabilizer. 
Among all formulation F15 was optimized; % drug 
content, % Solubility, % Yield, Particle size (µm) 
was found to be 91.84±3.54, 92.58±3.12, 
90.36±1.98, 1.34±0.16 respectively. Particle size of 
F15 formulation was found to be 358.2 nm and PDI 
of the formulation was 0.200.
Poloxamer F68 was the most effective stabilizer for 
poorly soluble drugs. Poloxamers have a linear 
ABA triblock polymer chain (A stands for 
hydrophilic polyethylene oxide (PEO) segment and 
B stands for hydrophobic polypropylene oxide 
(PPO) segment). The hydrophobic PPO chains can 
drive the polymer to adsorb on the surface of drug 
particles, while the hydrophilic PEO chains 
surround the drug particles providing steric 
hindrance against aggregation. Pluronic® F68 has a 
lower molecular weight compared to other 
pluronics which may exert less kinetic restriction in 
the adsorption process and faster diffusion. 
Percentage drug release of nanosuspension was 
higher and faster as compare to pure drug that was 
76.52±2.85 in 180 minutes. Drug release studies of 
pure Clopidogrel and prepared nanosuspension (F 
15) were calculated from release profile are 
reported in Figure 8. From this data, it was evident 
that onset of drug release of pure Clopidogrel was 
very low as compare to its nanosuspension. 
Physical appearance of the F15 nanosuspension did 
not change when samples were stored at specified 
conditions. A loose, thin layer of sediment was 
observed when nanosuspension was stored at room 
temperature for 1 and 2 months. However, the 
sediment layer disappeared with slight hand 
shaking. On performing stability study, it can be 
inferred from the observed data that the prepared 
nanosuspension (F 15) was passed the stability test 
and was stable at different conditions.
CONCLUSION:
The Precipitation method offers a direct process to 
obtain drug nanoparticles of desirable size, 
amenable for continuous and consistent production. 
Clopidogrel (anti-platelet) in nano-suspension 
formulation can overcome the limitation of low 
solubility, dissolution and bioavailability. Hence 
Antisolvent -precepitation method can be used as 
an effective tool for preparation of nanosized 
formulations. Clopidogrel nanosuspension prepared 
by this method showed significant improvement in 
aqueous solubility as well as dissolution 
characteristics which may significantly improve its 
solubility. 
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